By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian diagnostics firm Med BioGene today said its net loss rose 11 percent in the second quarter.

For the three months ended June 30, the company posted no revenues, the same as a year ago. Net loss totaled C$551,910 ($524,266), or C$0.01 per share for the quarter, compared to C$497,503, C$0.01 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.